Skip to main content
. 2019 Nov 14;20(22):5720. doi: 10.3390/ijms20225720

Table 1.

Patient and tumor characteristics.

Characteristic TCGA Discovery Dataset (n = 330) TCGA Validation Dataset (n = 196)
No. % No. %
Status
Alive 258 78.2 109 55.6
Dead 72 21.8 87 44.4
Sex
Male 214 64.8 127 64.8
Female 116 35.2 69 35.2
Tumor stage
Stages I and II 222 67.3 98 50.0
Stages III and IV 108 32.7 98 50.0
Age, years
Median 60 62
Range 26–90 34–85
Non-silent mutations in VHL (Von Hippel–Lindau Tumor Suppressor)
Yes 150 45.5
No 180 54.5
Non-silent mutations in PBRM1 (Polybromo 1)
Yes 128 38.8
No 202 61.2
Non-silent mutations in TTN (Titin)
Yes 58 17.6
No 272 82.4
Non-silent mutations in SETD2 (SET Domain Containing 2)
Yes 39 11.8
No 291 88.2
Non-silent mutations in BAP1 (BRCA1 Associated Protein 1)
Yes 29 8.8
No 301 91.2